Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Gains from Investment Securities (2017 - 2024)

Historic Gains from Investment Securities for Puma Biotechnology (PBYI) over the last 8 years, with Q3 2024 value amounting to $441430.0.

  • Puma Biotechnology's Gains from Investment Securities fell 2410.26% to $441430.0 in Q3 2024 from the same period last year, while for Dec 2024 it was -$1000.0, marking a year-over-year increase of 5000.0%. This contributed to the annual value of $581614.0 for FY2023, which is 12.69% down from last year.
  • Per Puma Biotechnology's latest filing, its Gains from Investment Securities stood at $441430.0 for Q3 2024, which was down 2410.26% from $441430.0 recorded in Q2 2024.
  • Puma Biotechnology's 5-year Gains from Investment Securities high stood at $5.4 million for Q1 2021, and its period low was -$1000.0 during Q4 2021.
  • For the 5-year period, Puma Biotechnology's Gains from Investment Securities averaged around $1.8 million, with its median value being $581614.0 (2023).
  • Examining YoY changes over the last 5 years, Puma Biotechnology's Gains from Investment Securities showed a top increase of 10825280.0% in 2021 and a maximum decrease of 10153.85% in 2021.
  • Over the past 5 years, Puma Biotechnology's Gains from Investment Securities (Quarter) stood at $65000.0 in 2020, then plummeted by 101.54% to -$1000.0 in 2021, then soared by 58335.3% to $582353.0 in 2022, then dropped by 0.13% to $581614.0 in 2023, then dropped by 24.1% to $441430.0 in 2024.
  • Its Gains from Investment Securities was $441430.0 in Q3 2024, compared to $441430.0 in Q2 2024 and $441430.0 in Q1 2024.